The significance of genetics for cholangiocarcinoma development
- PMID: 25332972
- PMCID: PMC4200671
- DOI: 10.3978/j.issn.2305-5839.2012.10.04
The significance of genetics for cholangiocarcinoma development
Abstract
Cholangiocarcinoma (CCA) is a rare malignancy of the liver, arising from bile ducts. The incidence is increasing worldwide, but the prognosis has remained dismal and virtually unchanged in the past 30 years. Although several risk factors have been associated with the development of this cancer, none of them are normally identified in most patients. Diagnosis in advanced stages of the disease and limited therapeutic options contribute to poor survival rates. The recent analysis of genetic and epigenetic alterations occurring in CCA has shed new light in the understanding of the molecular mechanisms leading to the malignant transformation of biliary cells. Further studies in this direction may foster new diagnostic, prognostic and therapeutic approaches. This review provides a global overview of recent advances in CCA and describes the most important genetic mutations and epigenetic alterations so far reported in CCA.
Keywords: Genetics; cholangiocarcinoma (CCA).
Similar articles
-
Epigenetic aberrations in cholangiocarcinoma: potential biomarkers and promising target for novel therapeutic strategies.Asian Pac J Cancer Prev. 2012;13 Suppl:41-5. Asian Pac J Cancer Prev. 2012. PMID: 23480763 Review.
-
Genetic and epigenetic abnormalities in primary sclerosing cholangitis-associated cholangiocarcinoma.Inflamm Bowel Dis. 2013 Jul;19(8):1789-97. doi: 10.1097/MIB.0b013e318281f49a. Inflamm Bowel Dis. 2013. PMID: 23615529 Review.
-
A review of the clinical diagnosis and therapy of cholangiocarcinoma.J Int Med Res. 2014 Feb;42(1):3-16. doi: 10.1177/0300060513505488. Epub 2013 Dec 23. J Int Med Res. 2014. PMID: 24366497 Review.
-
Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):233-44. doi: 10.1016/j.bpg.2015.02.002. Epub 2015 Feb 17. Best Pract Res Clin Gastroenterol. 2015. PMID: 25966424 Review.
-
Cholangiocarcinoma in patients with primary sclerosing cholangitis.Curr Opin Gastroenterol. 2020 Mar;36(2):77-84. doi: 10.1097/MOG.0000000000000616. Curr Opin Gastroenterol. 2020. PMID: 31850928 Review.
Cited by
-
Perioperative Management of Hilar Cholangiocarcinoma.J Gastrointest Surg. 2015 Oct;19(10):1889-99. doi: 10.1007/s11605-015-2854-8. Epub 2015 May 29. J Gastrointest Surg. 2015. PMID: 26022776 Free PMC article. Review.
-
Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism.J Exp Med. 2020 Aug 3;217(8):e20191779. doi: 10.1084/jem.20191779. J Exp Med. 2020. PMID: 32453420 Free PMC article.
-
Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells.Cancer Res Treat. 2021 Apr;53(2):457-470. doi: 10.4143/crt.2020.585. Epub 2020 Oct 7. Cancer Res Treat. 2021. PMID: 33070556 Free PMC article.
-
Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma.Curr Drug Targets. 2017;18(8):958-963. doi: 10.2174/1389450116666150223162737. Curr Drug Targets. 2017. PMID: 25706257 Free PMC article. Review.
-
Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma.Cells. 2020 Mar 4;9(3):614. doi: 10.3390/cells9030614. Cells. 2020. PMID: 32143356 Free PMC article. Review.
References
-
- Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005;128:1655-67. - PubMed
-
- Mosconi S, Beretta GD, Labianca R, et al. Cholangiocarcinoma. Crit Rev Oncol Hematol 2009;69:259-70. - PubMed
-
- Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet 2005;366:1303-14. - PubMed
-
- Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95:204-7. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous